SPORANOX by Johnson & Johnson is mechanism of action in vitro studies have demonstrated that itraconazole inhibits the cytochrome p450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes. Approved for the following fungal infections in immunocompromised, non-immunocompromised patients: blastomycosis, pulmonary and 11 more indications. First approved in 1999.
Drug data last refreshed 3m ago · AI intelligence enriched 2w ago
SPORANOX (itraconazole) is an injectable antifungal agent that inhibits cytochrome P450-dependent ergosterol synthesis in fungal cell membranes. It treats serious systemic fungal infections including blastomycosis, histoplasmosis, and aspergillosis in immunocompromised and non-immunocompromised patients, as well as onychomycosis (nail fungal infections). The drug is a small-molecule azole with broad-spectrum activity against multiple fungal pathogens.
SPORANOX is approaching loss of exclusivity with modest commercial performance ($197K in competitive set spending), signaling a consolidating team focused on managed care and existing patient retention.
Mechanism of Action In vitro studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes.
Worked on SPORANOX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
SPORANOX offers limited career growth due to its LOE-approaching status and low linked job count; roles available are predominantly defensive (market access, managed care, field sales) rather than growth-oriented. Working on this asset suits professionals seeking stability in specialty antifungal markets or those transitioning into generics/biosimilar management.